This cross-sectional study assesses the frequency of reporting of primary end point changes among active oncology phase 3 randomized clinical trials. Click to show full abstract
This cross-sectional study assesses the frequency of reporting of primary end point changes among active oncology phase 3 randomized clinical trials.
               
Click one of the above tabs to view related content.